Timing Your Exit Around GLP-1 Demand
How to read whether to sell into today's metabolic-health surge or build recurring revenue first, so you choose the window with your eyes open.
Read your readiness →
Home / Who We Serve / Endocrinology
Tier-1 Specialty · Sell-Side M&A
Sell Your Endocrinology Practice for What Its Chronic-Care Demand Is Truly Worth
A confidential, sell-side-exclusive process built around the long-term patient panels, recurring care, and metabolic-health demand that make endocrinology valuable. Sell-side only. We represent you, never the buyer.
What's your endocrinology practice actually worth?
A confidential ballpark in under two minutes, no email required.
Why Endocrinology Is Different
Why an endocrinology practice is valued differently.
Endocrinology sits at the center of two of the strongest demand stories in medicine right now: the surge in GLP-1 weight-loss treatment and the broader move toward metabolic and hormonal health. That demand is real, but it has not produced a published endocrinology valuation benchmark or a private-equity roll-up platform the way med spas or dermatology groups have. There is no specialty multiple to point to. So value rests on your actual adjusted earnings, the durability of your patient panel, and how much of your revenue is recurring chronic-care and cash-pay wellness rather than one-time insurance-billed visits.
Stable, Long-Term Panels
Diabetes, thyroid, and metabolic conditions are chronic and lifelong, so endocrinology panels return month after month. Buyers pay for that predictability because a long-tenured panel is recurring revenue that does not have to be re-won each year.
The Cash-Pay Wellness Pivot
GLP-1 weight management, hormone optimization, and metabolic wellness add cash-pay revenue on top of insurance-billed visits. The more of your income from durable cash-pay services rather than reimbursement alone, the stronger your position with buyers.
Referral-Hub Gravity
Endocrinology practices serve as referral hubs for primary care, cardiology, OB-GYN, and surgical specialties. That inbound network is hard for a buyer to replicate, and we document it as a defensible source of new patients rather than letting it go unpriced.
Payer Mix & Reimbursement Clarity
Two practices with the same revenue can be worth very different amounts once payer contracts, fee schedules, and reimbursement exposure are examined. We clean up and present your revenue cycle so financial stability reads as a strength, not a question mark.
| Earnings (the foundation) | Normalized true bottom-line profitability (adjusted EBITDA, or seller's discretionary earnings for smaller practices) | Everything builds from real cash flow |
| The proxy range (labeled, illustrative) | General medical-practice proxy: roughly 6x to 12x adjusted EBITDA, or about 0.5x to 1.0x annual revenue for smaller practices | Proxy bands, not a benchmark |
| What moves you up or down | Recurring chronic-care and cash-pay mix, low owner-dependence, documented multi-site systems, provider retention, clean financials | Top vs. bottom of range |
Estimate only, not a formal valuation, appraisal, or offer. An automated ballpark from limited inputs plus a labeled medical-practice proxy. Flagged verticals like endocrinology are directional only. Figures are presented as ranges by design. Your real number comes from a confidential, practice-specific analysis.
How Value Is Built
We label the proxy plainly, then tighten it for you.
Position rises with recurring chronic-care and cash-pay mix, low owner-dependence where you oversee while providers deliver care, multiple sites with documented systems, and clean multi-year financials. It falls with heavy owner-performed clinical work, thin recurring revenue, a single undocumented site, and reimbursement or GLP-1 commoditization exposure. Your confidential report normalizes your earnings and shows exactly which moves widen the spread in your favor.
Run my numbers →See Your Number First
Know your number before anyone else does.
A confidential ballpark in under two minutes. No email required to see your range. The estimate is generated on your device. Nothing is stored or sent unless you choose to continue.
Step 1 · Instant ballpark
$3.0M
Estimated enterprise value
$1.4M – $4.7M
Practices like yours trade around 2.6x – 5.3x adjusted earnings.
What raises your number
- Build recurring revenue past 30% of sales
- Reduce owner-performed treatment dependence
- Clean, normalized three-year financials
What lowers your number
- Owner performs the majority of clinical work
- Recurring revenue under 15% of sales
Step 2 · What you receive when you continue
Your custom valuation report. Comparable transactions, your likely buyer pool, and timing analysis.
Your buyer-readiness scorecard. The specific moves that raise your multiple before you go to market.
A confidential 30-minute strategy call with Bill Walker. No obligation, no pressure.
Your information is never shared, and we have never broken a client's confidentiality.
Estimate only. A ballpark from limited inputs plus published industry M&A benchmarks.
Endocrinology Sellers Ask
Everything that moves your number, in plain English.
Turning Chronic Care Into Recurring Revenue
Why long-term diabetes and thyroid panels are your most valuable asset, and how we price that durable, returning demand for a buyer.
Run the estimator →Adding Cash-Pay Wellness Before a Sale
How medical weight management and hormone optimization shift your revenue mix toward the durable cash-pay income buyers reward.
See what buyers reward →Reducing Owner-Dependence: The #1 Discount
Why a practice that runs on a provider team, not the founder, earns a meaningfully higher position, and how to shift care and loyalty off you.
Test the impact →Cleaning Up Payer Contracts & the Revenue Cycle
How fee schedules, billing practices, and reimbursement exposure are read by a buyer's diligence team, and how we present them as strength.
Our diligence prep →Who Actually Buys Endocrinology Practices
Strategic acquirers and investors seeking metabolic-health exposure, and what each one values, so you know who is really at the table.
Meet the buyers →Endocrinology Track Record · Anonymized
Discretion is the proof.
Single-location Endocrinology
$00.0M
Sell-side advisor
Chronic-care Endocrinology
$00.0M
Sell-side advisor
Multi-site Endocrinology
$00.0M
Sell-side advisor
Endocrinology + Metabolic Wellness
$00.0M
Sell-side advisor
Tombstone values redacted by design. The published board uses Aesthetic Brokers' verified, client-consented anonymized deals only.
Endocrinology Sell-Side Intelligence
What Makes Selling an Endocrinology Practice Different
Endocrinology is not a cosmetic specialty, and selling an endocrinology practice is nothing like selling a med spa or a dermatology group. The buyer pool is different. The value drivers are different. The risks that kill deals are different. Here is what a specialist sees that a generalist broker typically misses, and why it matters to your outcome.
Value Driver: Chronic Panels Are a Different Asset Class
A med spa sells a service. An endocrinology practice sells a relationship. Diabetes, thyroid dysfunction, and metabolic disease are lifelong conditions. Your panel returns month after month, year after year, without you re-acquiring it. Buyers who understand chronic-care practices read this as recurring revenue with low churn, not just patient volume. Generalist brokers often present it as headcount. The distinction matters when you sit across the table from a serious acquirer.
Value Driver: GLP-1 and Metabolic Health Demand
The surge in weight-management and metabolic-health demand is real, and it is pushing buyers toward endocrinology. But buyers are not paying for hype. They are paying for durable, recurring cash-pay programs layered onto your insurance-billed panel. Medical weight management with monthly follow-up, hormone optimization, and metabolic wellness subscriptions signal revenue that persists beyond a single prescription cycle. A practice with that structure occupies a different position than one whose GLP-1 revenue is transactional and tied to a single payer decision.
Risk That Depresses Value: Owner-Performed Clinical Work
In most specialties, a high-producing owner is a selling point. In endocrinology, a founder who personally manages the majority of chronic-care patients is a liability to a buyer, because the relationship walks out the door when you do. Practices where care runs through an NPA, PA, or associate physician team, and where the founder has shifted into an oversight and growth role, hold their position in diligence. Practices where the founder is the clinical center of gravity get discounted to account for panel attrition post-close. We build your transition narrative before the process starts, not after a buyer flags it.
What a Specialist Sees That a Generalist Broker Misses
A generalist broker will present your revenue, apply a proxy multiple, and show it to whoever is in their contact list. What they miss: the referral network your practice anchors, the reimbursement exposure buried in your payer contract mix, the GLP-1 revenue that reads as durable to one buyer and fragile to another, and the distinction between a chronic-care panel and a transaction-based patient base. We position each of these precisely, in language a strategic acquirer or investor in metabolic-health demand actually uses, because how your story is framed at first contact sets the floor for every negotiation that follows.
Endocrinology Sale FAQ
Straight answers, before you commit to anything.
An endocrinology practice is valued on its adjusted earnings with a multiple applied on top. Because no published endocrinology multiple exists, we apply a clearly labeled general medical-practice proxy of roughly 6x to 12x adjusted EBITDA, or about 0.5x to 1.0x revenue for smaller practices. Recurring chronic-care and cash-pay revenue move you toward the higher end. It is always a range, never a single number.
No. There is no endocrinology-specific valuation benchmark and no private-equity roll-up platform setting a market price for the sector. We value your practice against a labeled general medical-practice proxy and say so plainly, rather than presenting a number as sourced specialty data. The proxy is directional only, and your practice may be worth more or less.
GLP-1 and metabolic-health demand can raise your value, but mainly through revenue quality, not hype. Buyers reward durable cash-pay weight management and hormone services layered onto your insurance-billed care, not one-time prescriptions. Demand tied to a single medication or reimbursement decision is discounted, while recurring programs with monthly follow-up and complementary services strengthen your position and your multiple.
Buyers value endocrinology practices for stable, long-term patient panels with chronic-care needs, recurring revenue, cash-pay wellness expansion potential, and their role as referral hubs for multiple specialties. Growing metabolic disease prevalence adds demand. Practices that run on a provider team rather than the founder, with clean financials and strong staff retention, are the most sought after.
Yes. A valuation begins with a confidential consultation, and nothing is shared with any buyer until you decide you are ready. You get the same view a buyer’s quality-of-earnings team would have, but privately and on your terms. Many owners get a valuation simply to know where they stand, with no obligation to sell.
No, not unless and until you choose to tell them. We treat confidentiality as part of protecting your value. Premature disclosure can unsettle staff, shake patient confidence, and weaken referral relationships, so we use confidentiality agreements, secure data rooms, and a vetted buyer process. You decide what is shared, with whom, and when.
Who you work with
You are advised by Bill Walker, not handed to a junior associate.
Bill Walker founded Aesthetic Brokers after leading mergers and acquisitions for a large private-equity-backed healthcare services organization. Before that he flew for the Marine Corps at the Presidential Helicopter Squadron and commanded a squadron in combat. He knows how an investor values a practice, and how to make sure that value lands with you, not the buyer.
Talk with Bill about your practiceYour endocrinology practice deserves an uncommon partner.
Start with a confidential, two-minute read on where you stand.